NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Heart Disease Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Heart Disease Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Elsevier



Screening for left ventricular dysfunction may have less value than thought



July 5th, 2009

The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction, reports a study in the June issue of the Journal of Cardiac Failure published by Elsevier.

In the study,1012 primary care patients with hypertension and/or diabetes without signs or symptoms of heart failure were screened for asymptomatic left ventricular dysfunction (ALVD), using measurements of NT-pro-BNP and echocardiography. Diastolic dysfunction was found in 368 subjects (36%) and was categorized as...


Source: Heart Disease Weekly (2009-07-05)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login